Helix Acquisition Corp. II to merge with BridgeBio Oncology Therapeutics in $461M deal

BridgeBio Oncology Therapeutics, Inc.

Equity value of $461M; BBOT stockholders to receive shares of PubCo common stock.
PIPE investments of ~$260M committed, including $75M from Cormorant; minimum $400M cash required at close.
Closing expected after SEC effectiveness, shareholder approvals, and Nasdaq listing; drop-dead date Oct 31, 2025.
Sponsor to forfeit shares if Helix Closing Cash < $400M; non-redemption agreements cover 450,900 Class A shares.
Lock-up on Sponsor and existing Helix investors' shares for one year post-Closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.